- Home
- TCBX vs BCYC Comparison
TCBX vs BCYC Comparison
Compare TCBX & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCBX
- BCYC
- Stock Information
- Founded
- TCBX 2008
- BCYC 2009
- Country
- TCBX United States
- BCYC United Kingdom
- Employees
- TCBX N/A
- BCYC N/A
- Industry
- TCBX Banks
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- TCBX Finance
- BCYC Health Care
- Exchange
- TCBX Nasdaq
- BCYC Nasdaq
- Market Cap
- TCBX 481.8M
- BCYC 565.5M
- IPO Year
- TCBX 2021
- BCYC 2019
- Fundamental
- Price
- TCBX $36.66
- BCYC $6.51
- Analyst Decision
- TCBX Hold
- BCYC Buy
- Analyst Count
- TCBX 4
- BCYC 11
- Target Price
- TCBX $41.67
- BCYC $20.73
- AVG Volume (30 Days)
- TCBX 68.5K
- BCYC 318.0K
- Earning Date
- TCBX 10-22-2025
- BCYC 10-30-2025
- Dividend Yield
- TCBX N/A
- BCYC N/A
- EPS Growth
- TCBX 38.90
- BCYC N/A
- EPS
- TCBX 3.56
- BCYC N/A
- Revenue
- TCBX $192,224,000.00
- BCYC $28,339,000.00
- Revenue This Year
- TCBX $24.66
- BCYC N/A
- Revenue Next Year
- TCBX $17.56
- BCYC N/A
- P/E Ratio
- TCBX $10.53
- BCYC N/A
- Revenue Growth
- TCBX 20.96
- BCYC N/A
- 52 Week Low
- TCBX $25.17
- BCYC $6.10
- 52 Week High
- TCBX $41.25
- BCYC $25.39
- Technical
- Relative Strength Index (RSI)
- TCBX 43.62
- BCYC 36.29
- Support Level
- TCBX $35.77
- BCYC $6.10
- Resistance Level
- TCBX $40.58
- BCYC $9.08
- Average True Range (ATR)
- TCBX 1.44
- BCYC 0.54
- MACD
- TCBX -0.11
- BCYC -0.24
- Stochastic Oscillator
- TCBX 20.76
- BCYC 12.92
About TCBX Third Coast Bancshares Inc.
Third Coast Bancshares Inc is a bank holding company. It focuses on providing commercial banking solutions to small and medium-sized businesses and professionals with operations in its markets. The bank operates eleven branches in the Greater Houston, Dallas-Fort Worth, and Austin-San Antonio markets, and one branch in Detroit, Texas. The company operates through one segment, community banking, It generates the majority of its revenue from interest on loans, customer service, and loan fees.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.